Product Description
A potent and selective small molecule inhibitor targeting tumors harboring KRAS G12D mutation, a pivotal driver of cancer progression in numerous malignancies. "Preclinical studies indicate that TSN1611 has the potential to make a meaningful difference in the lives of patients with KRAS G12D driven cancers, and we are excited to share our findings with the scientific and medical community," said Tony Zhang, Ph.D., CEO of Tyligand Bioscience. "We remain committed to advancing its development with quality and speed for the global cancer patients in need". (Sourced from: https://en.tyligand.com.cn/tyligand-news/news-release/tyligand-tsn1611-kras-g12d-inhibitor-fda-ind-clearance-aacr-2024)
Mechanisms of Action: KRAS G12D Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Tyligand Bioscience (Shanghai)
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: Colorectal Cancer|Non-Small-Cell Lung Cancer|Pancreatic Cancer|Small Cell Lung Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| TSN1611-2023-101 | P2 |
Recruiting |
Pancreatic Cancer|Colorectal Cancer|Small Cell Lung Cancer|Non-Small-Cell Lung Cancer |
2026-10-30 |